Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisPRNewsWire • 03/28/24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsPRNewsWire • 03/14/24
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 03/11/24
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial OfficerPRNewsWire • 01/09/24
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 12/20/23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsPRNewsWire • 11/08/23
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon AdvisorsPRNewsWire • 11/02/23
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business HighlightsPRNewsWire • 10/31/23
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/26/23
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney DiseasePRNewsWire • 10/25/23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial UpdatePRNewsWire • 09/26/23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsPRNewsWire • 08/25/23